在口服葡萄糖耐受性测试期间,在青少年中模拟葡萄糖,胰岛素,C-和乳酸酸相互作用
Jacopo Bonet1, Emiliano Barbieri2, Nicola Santoro3,4
1Department of Information Engineering, University of Padua, Padova, Italy.
Journal of diabetes science and technology
|July 30, 2024
概括
乳酸在代谢疾病中起着关键作用. 这项研究开发了葡萄糖-胰岛素-乳酸盐相互作用的模拟器,以帮助开发治疗肥胖和糖尿病等疾病的药物.
科学领域:
- 生物医学建模模型
- 代谢性疾病研究研究.
- 药理动力学是什么 药理动力学
背景情况:
- 乳酸盐因其在代谢性疾病 (包括肥胖和糖尿病) 中的作用而越来越受认可.
- 目前的模型缺乏模拟食后葡萄糖-胰岛素-乳酸盐动态的能力.
- 需要工具来研究病理条件下的乳酸代谢.
研究的目的:
- 开发一个模拟葡萄糖-胰岛素-C--乳酸盐相互作用的计算模型.
- 为研究针对乳酸代谢的药物疗法创建一个工具.
主要方法:
- 帕多瓦2型糖尿病模拟器 (T2DS) 被调整为包括葡萄糖-乳酸盐动力学.
- 产生了100个in silico受试者的人口.
- 该模型与接受口服葡萄糖耐受性测试 (OGTT) 的青少年的临床数据进行了验证.
主要成果:
- 开发的模型准确地预测了葡萄糖,胰岛素,C-和乳酸的时间过程.
- 实现了精确的模型参数估计 (CV% = 19%的中位数).
- 在 silico 种群表明与 AUC 和参数分布的临床数据有很好的一致性.
结论:
- 在OGTT期间开发了一种新的葡萄糖,胰岛素,C-和乳酸动力学的模拟器.
- 模拟器准确地捕捉到人口行为和主体间的变化.
- 这种工具可以用于研究针对乳酸代谢途径的药物药理学.
相关概念视频
Glucose Homeostasis: Regulation of Blood Glucose
1.5K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
1.5K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.2K
Hormones Regulating Blood Glucose
3.2K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.2K
Hypoglycemia and Glucagon
229
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
229
Oral Hypoglycemic Agents: Glinides
150
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
150
Glucagon-like Receptor Agonists
312
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
312


